CrossRef

Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Cancers 13(17) (2021)

Sara Atwa; Margarete Odenthal; Hend El Tayebi

Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population

Pharmacological Reports 68(2) (2016)

Emma Gbandi; Antonis Goulas; Vassilios Sevastianos; Stephanos Hadziyannis; Athanasia Panderi; John Koskinas; George Papatheodoridis; Themistoklis Vasiliadis; Dimitrios Agapakis; Andreas Protopapas; Panagiota Ioannidou; George Zacharakis; Emmanuil Sinakos; Sotiris Koutsounas; Georgios Germanidis

Untitled

The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs

Epilepsy Research 108(6) (2014)

Minzhi Li; Jinjing Tan; Xiaoqing Yang; Li Su; Juanjuan Xie; Baoyun Liang; Jianxiong Long; Haiyun Jiang; Qiugui Wei; Tingting Shen; Qing Chen; Yan Yan; Guangliang Wu; Lian Gu

Association of p-glycoprotein and bile salt export pump gene polymorphisms with advanced liver disease in hepatitis C virus infected patients

Memórias do Instituto Oswaldo Cruz 121 (2026)

Letícia Bomfim Campos; Nathália Alves Araújo de Almeida; Marcia Maria Amendola Pires; Carlos Eduardo Brandão-Mello; Livia Melo Villar; José Júnior França de Barros; Vanessa Salete de Paula

Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study

Cancer Chemotherapy and Pharmacology 79(4) (2017)

Mahamadou Tandia; Asma Mhiri; Bernard Paule; Raphaël Saffroy; Valérie Cailliez; Gaëlle Noé; Robert Farinotti; Laurence Bonhomme-Faivre